Format

Send to

Choose Destination
J Clin Lipidol. 2019 Mar - Apr;13(2):231-245. doi: 10.1016/j.jacl.2019.01.011. Epub 2019 Jan 30.

Management of dyslipidemia in adult solid organ transplant recipients.

Author information

1
Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
2
Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA. Electronic address: duellb@ohsu.edu.

Abstract

Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.

KEYWORDS:

Drug-drug interactions; Dyslipidemia; Immunosuppression; Lipid-lowering therapy; Solid organ transplantation

PMID:
30928441
DOI:
10.1016/j.jacl.2019.01.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center